The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•23 March 2026•

1 min read

Viatris Secures First-Ever Approval for GAD Treatment in Japan with Effexor SR

Icy Unilever headquarters with gears and clocks on a world map background. Signs read 'HIRING PAUSED' and 'FROZEN'. People work at computers below.

Key Facts

1Japan's Ministry of Health, Labour and Welfare (MHLW) approved Effexor SR 37.5 mg / 75 mg capsules for the treatment of adults with generalized anxiety disorder (GAD).

Viatris Inc. (Nasdaq: VTRS) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor SR for the treatment of adults with Generalized Anxiety Disorder (GAD). This milestone makes Effexor the first and only pharmacological treatment option specifically approved for GAD in the Japanese market. The approval covers the 37.5 mg and 75 mg capsule formulations of the serotonin-noradrenaline reuptake inhibitor (SNRI). This regulatory win addresses a significant unmet medical need in Japan's mental health sector, providing a new clinical path for patients. For Viatris, the approval grants a strategic first-mover advantage in a major global pharmaceutical market, opening a new revenue stream. The company expects this expansion to strengthen its international portfolio and drive long-term growth within its Japanese operations.